Related Experiment Video
Updated: May 28, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
P450(BM3) (CYP102A1): connecting the dots.
Christopher J C Whitehouse1, Stephen G Bell, Luet-Lok Wong
1Department of Chemistry, University of Oxford, Inorganic Chemistry Laboratory, South Parks Road, Oxford OX1 3QR, UK.
This review details the engineering of P450(BM3) (CYP102A1), a versatile enzyme, for catalyzing diverse chemical oxidations. It highlights advancements in understanding its mechanisms and applications in producing fine chemicals and pharmaceuticals.
Area of Science:
- Biochemistry and Molecular Biology
- Enzyme Engineering
- Biocatalysis
Background:
- P450(BM3) (CYP102A1) from Bacillus megaterium is a well-studied fatty acid hydroxylase.
- Extensive research over four decades has focused on its catalytic versatility.
- The enzyme has been engineered for oxidizing a wide range of non-natural substrates.
Purpose of the Study:
- To provide a comprehensive review of P450(BM3) research.
- To consolidate disparate research themes into a historical context.
- To serve as an accessible gateway to the field of P450(BM3) engineering.
Main Methods:
- Enzyme redesign and mutagenesis strategies.
- X-ray crystallography for structural insights.
- Biochemical and biophysical characterization of enzyme variants.
Main Results:
- Engineered P450(BM3) variants catalyze oxidation of pharmaceuticals, terpenes, and alkanes.
- Structural studies elucidate catalytic effects of mutagenesis.
- Functional insights gained from altered reduction potentials and electron transfer rates.
Conclusions:
- P450(BM3) engineering offers significant potential for drug metabolite production and fine chemical synthesis.
- Ongoing research focuses on methane oxidation and improving selectivity.
- This review synthesizes historical and current research for future advancements.
More Related Videos
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
14:34A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Drug Metabolism: Phase I Reactions
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Hepatic Drug Clearance: Role of Transporters